| 000 | 01349 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513132838.0 | ||
| 264 | 0 | _c19980112 | |
| 008 | 199801s 0 0 eng d | ||
| 022 | _a0041-1337 | ||
| 024 | 7 |
_a10.1097/00007890-199712150-00024 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBuysmann, S | |
| 245 | 0 | 0 |
_aAdministration of OKT3 as a two-hour infusion attenuates first-dose side effects. _h[electronic resource] |
| 260 |
_bTransplantation _cDec 1997 |
||
| 300 |
_a1620-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnaphylatoxins _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aComplement Activation _xdrug effects |
| 650 | 0 | 4 |
_aComplement C3a _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aDyspnea _xchemically induced |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMuromonab-CD3 _xadministration & dosage |
| 650 | 0 | 4 |
_aNeutrophil Activation _xdrug effects |
| 700 | 1 | _aHack, C E | |
| 700 | 1 | _avan Diepen, F N | |
| 700 | 1 | _aSurachno, J | |
| 700 | 1 | _aten Berge, I J | |
| 773 | 0 |
_tTransplantation _gvol. 64 _gno. 11 _gp. 1620-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00007890-199712150-00024 _zAvailable from publisher's website |
| 999 |
_c9385148 _d9385148 |
||